Prab: CSV import

2025-03-17T09:02:42Z

CSV import

← Older revision		Revision as of 09:02, 17 March 2025
Line 27:		Line 27:
	{{No image}}		{{No image}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T13:42:46Z

CSV import

← Older revision		Revision as of 13:42, 10 February 2025
Line 25:		Line 25:

	{{pharmacology-stub}}		{{pharmacology-stub}}
			{{No image}}
	{{No image}}		{{No image}}

Prab: CSV import

2025-02-10T13:29:58Z

CSV import

← Older revision		Revision as of 13:29, 10 February 2025
Line 25:		Line 25:

	{{pharmacology-stub}}		{{pharmacology-stub}}
			{{No image}}

Prab: CSV import

2024-03-08T14:31:59Z

CSV import

New page

'''DelNS1-2019-nCoV-RBD-OPT''' is a [[recombinant vaccine]] candidate that is being developed for the prevention of [[COVID-19]], a disease caused by the [[SARS-CoV-2]] virus. This vaccine candidate is based on the [[DelNS1]] platform, which is a type of [[influenza virus]] vector that has been genetically modified to express the [[Receptor Binding Domain]] (RBD) of the SARS-CoV-2 virus.

==Development==
The DelNS1-2019-nCoV-RBD-OPT vaccine is being developed by researchers at the [[University of Hong Kong]]. The vaccine uses a [[genetically modified]] influenza virus, which has had the NS1 gene deleted (hence the name DelNS1), to carry the RBD of the SARS-CoV-2 virus into the body. The RBD is the part of the virus that binds to the [[ACE2 receptor]] on human cells, allowing the virus to enter the cell and cause infection. By presenting the RBD to the immune system, the vaccine aims to stimulate an immune response that will protect against COVID-19.

==Clinical Trials==
As of 2021, the DelNS1-2019-nCoV-RBD-OPT vaccine is in the preclinical stage of development. This means that it is being tested in the laboratory and in animal models to assess its safety and efficacy before it can be tested in humans. The results of these preclinical studies will determine whether the vaccine can proceed to [[clinical trials]].

==Mechanism of Action==
The DelNS1-2019-nCoV-RBD-OPT vaccine works by using the DelNS1 influenza virus as a vector to deliver the RBD of the SARS-CoV-2 virus to the body's immune system. The immune system then recognizes the RBD as foreign and mounts an immune response against it. This response includes the production of [[antibodies]] that can bind to the RBD and prevent it from binding to the ACE2 receptor, thereby preventing the virus from entering human cells and causing infection.

==Potential Advantages==
One potential advantage of the DelNS1-2019-nCoV-RBD-OPT vaccine is that it uses a proven vaccine platform. The DelNS1 platform has been used to develop vaccines for other diseases, including influenza, and has a good safety profile. Additionally, because the vaccine presents the RBD to the immune system, it may be able to stimulate a more targeted immune response than vaccines that present the whole virus.

==See Also==
* [[COVID-19 vaccine]]
* [[SARS-CoV-2]]
* [[Receptor Binding Domain]]
* [[ACE2 receptor]]

[[Category:COVID-19]]
[[Category:Vaccines]]
[[Category:Medical research]]
[[Category:Pharmacology]]

{{pharmacology-stub}}

DelNS1-2019-nCoV-RBD-OPT - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import

Prab: CSV import